BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26198912)

  • 1. Reduction of inflammation and preservation of neurological function by anti-CD52 therapy in murine experimental autoimmune encephalomyelitis.
    Turner MJ; Pang PT; Chretien N; Havari E; LaMorte MJ; Oliver J; Pande N; Masterjohn E; Carter K; Reczek D; Brondyk W; Roberts BL; Kaplan JM; Siders WM
    J Neuroimmunol; 2015 Aug; 285():4-12. PubMed ID: 26198912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment.
    Pant AB; Wang Y; Mielcarz DW; Kasper EJ; Telesford KM; Mishra M; Haque A; Channon JY; Kasper LH; Begum-Haque S
    J Neuroimmunol; 2017 Feb; 303():22-30. PubMed ID: 28087077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis.
    Simon M; Ipek R; Homola GA; Rovituso DM; Schampel A; Kleinschnitz C; Kuerten S
    J Neuroinflammation; 2018 Aug; 15(1):225. PubMed ID: 30098594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis.
    Wegner C; Stadelmann C; Pförtner R; Raymond E; Feigelson S; Alon R; Timan B; Hayardeny L; Brück W
    J Neuroimmunol; 2010 Oct; 227(1-2):133-43. PubMed ID: 20684995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
    von Kutzleben S; Pryce G; Giovannoni G; Baker D
    Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment With CD52 Antibody Protects Neurons in Experimental Autoimmune Encephalomyelitis Mice During the Recovering Phase.
    Hao W; Luo Q; Menger MD; Fassbender K; Liu Y
    Front Immunol; 2021; 12():792465. PubMed ID: 34975892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibiting repulsive guidance molecule-a suppresses secondary progression in mouse models of multiple sclerosis.
    Tanabe S; Fujita Y; Ikuma K; Yamashita T
    Cell Death Dis; 2018 Oct; 9(11):1061. PubMed ID: 30333477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-mouse CD52 monoclonal antibody ameliorates iron-deficient anaemia in IL-10 knockout mice.
    Wang H; Dong J; Zuo L; Liu J; Zhu W; Li Y; Gu L; Zhao J; Zhang L; Gong J; Zhang W; Li N; Li J
    Br J Nutr; 2014 Mar; 111(6):987-95. PubMed ID: 24160470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of antimouse CD52 monoclonal antibody on graft's γδ intraepithelial lymphocytes after orthotopic small bowel transplantation in mice.
    Shen B; Yu H; Hao X; Qu L; Cai X; Li N
    Transplantation; 2013 Mar; 95(5):663-70. PubMed ID: 23503501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune status following alemtuzumab treatment in human CD52 transgenic mice.
    Turner MJ; Lamorte MJ; Chretien N; Havari E; Roberts BL; Kaplan JM; Siders WM
    J Neuroimmunol; 2013 Aug; 261(1-2):29-36. PubMed ID: 23759318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic effect of anti-CD52 treatment in murine experimental autoimmune encephalomyelitis is associated with altered IL-33 and ST2 expression levels.
    Barbour M; Wood R; Hridi SU; Wilson C; McKay G; Bushell TJ; Jiang HR
    J Neuroimmunol; 2018 May; 318():87-96. PubMed ID: 29526407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate.
    Aharoni R; Vainshtein A; Stock A; Eilam R; From R; Shinder V; Arnon R
    J Autoimmun; 2011 Nov; 37(3):228-41. PubMed ID: 21752599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
    Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
    Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
    De Decker M; Bacher K; Thierens H; Slegers G; Dierckx RA; De Vos F
    Nucl Med Biol; 2008 Jul; 35(5):599-604. PubMed ID: 18589304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune cell derived BDNF does not mediate neuroprotection of the murine anti-CD52 antibody in a chronic autoimmune mouse model.
    Demir S; Pitarokoili K; Linker R; Gold R
    J Neuroimmunol; 2019 Mar; 328():78-85. PubMed ID: 30623801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity.
    Holgate RG; Weldon R; Jones TD; Baker MP
    PLoS One; 2015; 10(9):e0138123. PubMed ID: 26372145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.
    Forte M; Gold BG; Marracci G; Chaudhary P; Basso E; Johnsen D; Yu X; Fowlkes J; Rahder M; Stem K; Bernardi P; Bourdette D
    Proc Natl Acad Sci U S A; 2007 May; 104(18):7558-63. PubMed ID: 17463082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell depletion abrogates T cell-mediated demyelination in an antibody-nondependent common marmoset experimental autoimmune encephalomyelitis model.
    Jagessar SA; Heijmans N; Bauer J; Blezer EL; Laman JD; Hellings N; 't Hart BA
    J Neuropathol Exp Neurol; 2012 Aug; 71(8):716-28. PubMed ID: 22805775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimouse CD52 monoclonal antibody inhibits established spontaneous colitis in IL-10-deficient mice.
    Zhu WM; Li Y; Yu C; Li N; Li JS
    Inflamm Bowel Dis; 2011 Jul; 17(7):E72-3. PubMed ID: 21538714
    [No Abstract]   [Full Text] [Related]  

  • 20. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
    Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
    Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.